Log in
Log into your PedsMrkt account to access our Community forums.
If you don't see an email, please check your Junk folder. The email will be sent from support@pedsmrkt.com
IP License - Prognostic Gene Signature and Method for Diffuse Large B-Cell Lymphoma Prognosis and Treatment
IP Licensing
Availability: Available On Demand
For informational purposes only. Please contact seller directly for more details.
Share This:
Systems, treatment and prognostic methods, and kits for risk stratification and development of treatment options for diffuse large B-cell lymphoma patients. The systems, methods, and kits comprise determining, detecting, and evaluating gene expression values for a defined gene panel, or a subset thereof, detected in a biological sample from the patient and determining a risk score associated with the gene signature panel, which can be used to guide treatment of the patient.
Background: Diffuse large B-cell lymphoma (DLBCL) is an heterogenous cancer that can have profound differences in survival outcomes. Molecular profiling has allowed for the identification of DLBCL subclasses and together with clinical prognostic factors, such as the International Prognostic Index, have improved clinical care and survival. Despite these advances, a gene signature that is associated with overall survival (OS) and is reproducible across different DLBCL studies could better classify risk and predict OS. The Innovation: Gene expression and clinical parameters in the Lymphoma/Leukemia Molecular Profiling Project from individuals that received R-CHOP therapy were used to identify genes whose expression is associated with overall survival. This was further refined to develop a prognostic gene signature of 33 genes that could be used to calculate risk scores for each individual and predict overall survival. This prognostic gene signature was validated in 3 additional data sets and determined significant differences in overall survival in individuals with high or low risk scores.
A prognostic gene signature consisting of 33 genes that can stratify DLBCL patients receiving R-CHOP therapy into high or low risk groups that have significantly different Overall Survival (OS). This gene signature can be utilized to identify individuals that are at high risk of poor survival outcomes with DLBCL that could be candidates for experimental medicine and clinical trials and who should be more closely monitored clinically.
Advantages and Potential Applications: The unique molecular prognostic signature is useful for predicting DLBCL prognosis, regardless of subtype. The gene signature can be utilized to identify individuals that are at high risk of poor survival outcomes with DLBCL who could be candidates for experimental medicine and clinical trials and should be more closely monitored clinically. The 33-gene panel can also be used over time to provide an indication of disease progression and/or response to treatment
Status: PCT Patent Application filed October 27, 2021. US and EPO applications filed April 2023.
Publications: “A prognostic gene signature for predicting survival outcome in diffuse large B-cell lymphoma” Cancer Genetics, 252-253 (2021) 87-95
Licensing: Children’s Mercy, Kansas City seeks to have discussions with companies that are interested in licensing and/or research collaborations.
Resources
Shipping Information
Digital delivery/downloads will typically be delivered within 2 business days.
Physical products typically take 5-8 business days. Please contact the seller directly with any questions about your order.
You will receive an order confirmation email from PedsMrkt followed by a shipping email when your order ships.
Returns
Please contact the seller directly for their return policy and to
handle returns. Customer will be responsible for return shipping fees.
